Gene Variant Detail

Gene MET
Variant del exon14
Impact List deletion
Protein Effect gain of function
Gene Variant Descriptions MET del exon14 is a Met splice variant caused by a mutation resulting in the deletion of exon 14 (PMID: 16397241). Del exon14 results in both increased Met protein stability and ligand-dependent downstream signaling (PMID: 25971938).
Associated Drug Resistance

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET del exon14 MET Y1230C Advanced Solid Tumor sensitive Glesatinib Preclinical - Cell line xenograft Actionable In a preclinical study, transformed cells expressing MET deletion exon 14 and MET Y1230C were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 52% tumor regression in xenograft models (PMID: 28765324). 28765324
MET del exon14 TP53 R175H histiocytic and dendritic cell cancer predicted - sensitive Crizotinib Case Reports/Case Series Actionable In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET exon 14 skipping and TP53 R175H (PMID: 25971938). 25971938
KRAS over exp MET del exon14 stomach cancer predicted - resistant Crizotinib Preclinical - Cell culture Actionable In a preclinical study, gastric cancer cells harboring a MET exon 14 splice site mutation demonstrated some resistance to treatment with Xalkori (crizotinib) when overexpressing wild-type Kras in culture (PMID: 30072474). 30072474
MET del exon14 lung adenocarcinoma predicted - sensitive Crizotinib Case Reports/Case Series Actionable In a clinical study, three patients with lung adenocarcinoma harboring a MET exon 14 skipping mutation demonstrated partial responses when treated with Xalkori (crizotinib) (PMID: 25971939). 25971939
MET del exon14 stomach carcinoma sensitive Cabozantinib Preclinical - Cell culture Actionable In a preclinical study, Cometriq (cabozantinib) inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 non-small cell lung carcinoma sensitive Onartuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, Onartuzumab inhibited tumor growth and decreased MET expression in a non-small cell lung cancer xenograft model harboring a deletion of MET exon 14 (PMID: 23882082). 23882082
MET del exon14 Advanced Solid Tumor sensitive Crizotinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing a deletion of MET exon 14 were sensitive to Xalkori (crizotinib) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 colorectal cancer sensitive PHA-665752 Preclinical - Patient cell culture Actionable In a preclinical study, PHA-665752 inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 stomach carcinoma sensitive SAIT301 Preclinical - Patient cell culture Actionable In a preclinical study, SAIT301 inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 Advanced Solid Tumor sensitive Capmatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing a deletion of MET exon 14 were sensitive to Capmatinib (INC280) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 Advanced Solid Tumor sensitive Glesatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing deletion of MET exon 14 were sensitive to Glesatinib (MGCD265) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 colorectal cancer sensitive SAIT301 Preclinical - Patient cell culture Actionable In a preclinical study, SAIT301 inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 lung adenocarcinoma predicted - sensitive Glesatinib Case Reports/Case Series Actionable In a clinical case study, a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation demonstrated a 66% reduction in target lesion size and maintained a partial response for 7 months when treated with Glesatinib (MGCD265) (PMID: 28765324). 28765324
MET del exon14 stomach cancer sensitive Glesatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in gastric cancer cells harboring a deletion of MET exon 14 and amplification of the mutant allele in culture, and resulted in tumor regression in cell line xenograft models (PMID: 28765324). 28765324
MET del exon14 colorectal cancer sensitive Cabozantinib Preclinical - Patient cell culture Actionable In a preclinical study, Cometriq (cabozantinib) inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 lung squamous cell carcinoma predicted - sensitive Capmatinib Case Reports/Case Series Actionable In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring a MET exon 14 skipping mutation (PMID: 25971938). 25971938
MET del exon14 stomach carcinoma sensitive Crizotinib Preclinical - Patient cell culture Actionable In a preclinical study, Xalkori (crizotinib) inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 colorectal cancer sensitive Crizotinib Preclinical - Patient cell culture Actionable In a preclinical study, Xalkori (crizotinib) inhibited growth of patient-derived colorectal cancer cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 stomach cancer decreased response Emibetuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 stomach cancer sensitive SYM015 Preclinical - Cell line xenograft Actionable In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 lung cancer sensitive Glesatinib Preclinical - Cell culture Actionable In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in lung cancer cells harboring a deletion of MET exon 14 and loss of the wild-type MET allele in culture (PMID: 28765324). 28765324
MET del exon14 stomach carcinoma sensitive PHA-665752 Preclinical - Patient cell culture Actionable In a preclinical study, PHA-665752 inhibited growth of patient-derived gastric carcinoma cells harboring a MET exon 14 skipping mutation in culture (PMID: 26375439). 26375439
MET del exon14 lung cancer decreased response Emibetuzumab Preclinical - Pdx Actionable In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 non-small cell lung carcinoma sensitive KTN0073-IgG1 Preclinical - Cell culture Actionable In a preclinical study, KTN0073-IgG1 inhibited growth of a non-small cell lung cancer cell line harboring deletion of MET exon 14 in culture (PMID: 27550450). 27550450
MET del exon14 lung cancer sensitive SYM015 Preclinical - Pdx Actionable In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 non-small cell lung carcinoma predicted - sensitive Savolitinib Phase II Actionable In a Phase II trial, Savolitinib (AZD6094) treatmetn resulted in partial response in 51.6% (16/31) and stable disease in 32.3% (10/31) of patients with pulmonary sarcomatoid carcinoma (n=14) or other types of non-small cell lung cancer (n=20) harboring MET exon 14 skipping mutations (AACR Annual Meeting 2019, Abstract CT301; NCT02897479). detail...
MET del exon14 Advanced Solid Tumor sensitive SYM015 Preclinical - Pdx & cell culture Actionable In a preclinical study, Sym015 inhibited growth of cancer cell lines harboring a deletion of MET exon 14 in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models with deletion of MET exon 14 (Cancer Res July 15 2016 (76) (14 Supplement) 1219). detail...
CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H melanoma predicted - sensitive Carboplatin + Imatinib + Paclitaxel Case Reports/Case Series Actionable In a clinical case study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312). 28514312
MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S lung adenocarcinoma predicted - resistant Crizotinib Case Reports/Case Series Actionable In a clinical case study, a patient with lung adenocarcinoma harboring MET deletion exon 14 responded to Xalkori (crizotinib), demonstrating a near complete response at 3 months, however, after 9 months progression ensued and a re-biospy identified MET del exon14, MET amplification, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R (PMID: 28522754). 28522754
MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S lung adenocarcinoma predicted - resistant Crizotinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient harboring MET deletion exon 14 and MET amplification demonstrated resistance to Xalkori (crizotinib), and the patient was found to have acquired MET Y1230H, MET D1228N, MET Y1230S, and MET G1163R (PMID: 28765324). 28765324
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Crizotinib + Lapatinib + Linsitinib Preclinical - Patient cell culture Actionable In a preclinical study, the combination therapy of Xalkori (crizotinib), Tykerb (lapatinib), and Linsitinib (OSI-906) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Lapatinib Preclinical - Patient cell culture Actionable In a preclinical study, Tykerb (lapatinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Crizotinib + Lapatinib Preclinical - Patient cell culture Actionable In a preclinical study, the combination therapy of Xalkori (crizotinib) and Tykerb (lapatinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Gefitinib Preclinical - Patient cell culture Actionable In a preclinical study, Iressa (gefitinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Trametinib Preclinical - Patient cell culture Actionable In a preclinical study, Mekinist (trametinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Alpelisib Preclinical - Patient cell culture Actionable In a preclinical study, Alpelisib (BYL719) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Crizotinib + Linsitinib Preclinical - Patient cell culture Actionable In a preclinical study, the combination therapy of Xalkori (crizotinib) and Linsitinib (OSI-906) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Linsitinib Preclinical - Patient cell culture Actionable In a preclinical study, Linsitinib (OSI-906) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma predicted - resistant Crizotinib + Trametinib Preclinical - Patient cell culture Actionable In a preclinical study, the combination treatment of Xalkori (crizotinib) and Mekinist (trametinib) in non-small cell lung carcinoma patient-derived cells with KRAS amplification and a MET exon 14 splice site mutation led to increased Pi3k/Akt signaling, did not result in apoptotic induction, and only minimally reduced cell viability compared to Xalkori (crizotinib) treatment alone in culture (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Crizotinib + Gefitinib Preclinical - Patient cell culture Actionable In a preclinical study, the combination therapy of Xalkori (crizotinib) and Iressa (gefitinib) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma sensitive Copanlisib + Crizotinib Preclinical - Pdx & cell culture Actionable In a preclinical study, non-small cell lung carcinoma cells with KRAS amplification and a MET exon 14 splice site mutation treated with the combination therapy of Aliqopa (copanlisib) and Xalkori (crizotinib) demonstrated apoptotic activity and inhibition of cell proliferation in culture, and in patient-derived xenograft models, showed greater tumor growth inhibition compared to Xalkori (crizotinib) treatment alone (90.2% vs 69.4%, respectively) (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma no benefit Alpelisib + Crizotinib Preclinical - Patient cell culture Actionable In a preclinical study, the combination therapy of Xalkori (crizotinib) and Alpelisib (BYL719) treatment did not result in apoptotic induction or inhibition of cell proliferation in non-small cell lung carcinoma patient-derived cells harboring KRAS amplification and a MET exon 14 splice site mutation (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma predicted - sensitive Copanlisib Preclinical - Patient cell culture Actionable In a preclinical study, non-small cell carcinoma patient-derived cells with KRAS amplification and a MET exon 14 splice site mutation demonstrated some apoptotic activity and inhibition of proliferation in culture when treated with Aliqopa (copanlisib) (PMID: 30072474). 30072474
KRAS amp MET del exon14 non-small cell lung carcinoma resistant Crizotinib Case Reports/Case Series Actionable In a clinical study, a patient with non-small cell lung carcinoma harboring a MET exon 14 splice site mutation demonstrated an initial response to Xalkori (crizotinib) for 4 months, but then developed resistance, and was found to have acquired KRAS amplification, which was also confirmed in patient-derived cells in culture (PMID: 30072474). 30072474
MET del exon14 MET D1228N Advanced Solid Tumor sensitive Glesatinib Preclinical - Cell line xenograft Actionable In a preclinical study, transformed cells expressing MET deletion exon 14 and MET D1228N were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 21% tumor regression in xenograft models (PMID: 28765324). 28765324
MET del exon14 MET D1228N lung squamous cell carcinoma predicted - resistant Crizotinib Case Reports/Case Series Actionable In a clinical case study, a patient with squamous cell lung cancer harboring a MET exon 14 skipping mutation was determined to have acquired MET D1228N after progression on Xalkori (crizotinib) therapy (PMID: 27343442). 27343442
MET del exon14 TP53 N30fs lung large cell carcinoma predicted - sensitive Capmatinib Case Reports/Case Series Actionable In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET exon 14 skipping and TP53 N30fs*14 (PMID: 25971938). 25971938
MET amp MET del exon14 MET D1228N MET G1163R MET L1195V lung adenocarcinoma predicted - resistant Glesatinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient previously harboring MET amp, MET deletion exon 14, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R demonstrated a decrease in lesion size when treated with Glesatinib (MGCD265), however, progression ensued and plasma testing indicated the patient lost Y1230H and Y1230S, but acquired MET L1195V (PMID: 28765324). 28765324
MET amp MET del exon14 non-small cell lung carcinoma sensitive SCC244 Preclinical - Pdx Actionable In a preclinical study, non-small cell lung carcinoma patient derived xenograft (PDX) models co-harboring MET amplification and MET deletion of exon 14 were sensitive to SCC244 treatment, demonstrating a complete response in four and a partial response in another four (PMID: 29237805). 29237805
MET amp MET del exon14 lung cancer predicted - sensitive TPX-0022 Preclinical - Pdx Actionable In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of lung cancer harboring MET amplification and MET exon 14 deletion (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321). detail...
MET amp MET del exon14 lung adenocarcinoma predicted - sensitive Crizotinib Case Reports/Case Series Actionable In a clinical case study, a lung adenocarcinoma patient co-harboring MET exon 14 deletion and MET amp was sensitive to Xalkori (crizotinib), demonstrating a partial response for 8 months (PMID: 28765324). 28765324
MET amp MET del exon14 lung cancer sensitive Glesatinib Preclinical - Pdx Actionable In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET exon 14 deletion demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324). 28765324
MET amp MET del exon14 lung adenocarcinoma predicted - sensitive Cabozantinib Case Reports/Case Series Actionable In a clinical case study, a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and MET amplification demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939). 25971939
MET amp MET del exon14 non-small cell lung carcinoma sensitive Glesatinib Preclinical - Pdx Actionable In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring deletion of MET exon 14 and varying degrees of MET amplification (PMID: 28765324). 28765324